RemeGen Statistics

Total Valuation

RemeGen has a market cap or net worth of CNY 50.36 billion. The enterprise value is 51.36 billion.

Market Cap	50.36B
Enterprise Value	51.36B

Important Dates

The next estimated earnings date is Thursday, March 26, 2026.

Earnings Date	Mar 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	355.13M
Shares Outstanding	n/a
Shares Change (YoY)	+0.77%
Shares Change (QoQ)	+4.08%
Owned by Insiders (%)	12.41%
Owned by Institutions (%)	60.65%
Float	463.67M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	22.61
PB Ratio	21.71
P/TBV Ratio	23.26
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-54.20
EV / Sales	23.23
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-159.17

Financial Position

The company has a current ratio of 0.96, with a Debt / Equity ratio of 0.94.

Current Ratio	0.96
Quick Ratio	0.66
Debt / Equity	0.94
Debt / EBITDA	n/a
Debt / FCF	-6.76
Interest Coverage	-12.31

Financial Efficiency

Return on equity (ROE) is -40.42% and return on invested capital (ROIC) is -12.08%.

Return on Equity (ROE)	-40.42%
Return on Assets (ROA)	-9.72%
Return on Invested Capital (ROIC)	-12.08%
Return on Capital Employed (ROCE)	-28.90%
Revenue Per Employee	742,854
Profits Per Employee	-315,984
Employee Count	2,999
Asset Turnover	0.38
Inventory Turnover	0.53

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +159.44% in the last 52 weeks. The beta is 0.86, so RemeGen's price volatility has been lower than the market average.

Beta (5Y)	0.86
52-Week Price Change	+159.44%
50-Day Moving Average	94.76
200-Day Moving Average	67.84
Relative Strength Index (RSI)	55.60
Average Volume (20 Days)	4,926,614

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, RemeGen had revenue of CNY 2.23 billion and -947.63 million in losses. Loss per share was -1.75.

Revenue	2.23B
Gross Profit	1.86B
Operating Income	-908.63M
Pretax Income	-947.63M
Net Income	-947.63M
EBITDA	-636.46M
EBIT	-908.63M
Loss Per Share	-1.75

Full Income Statement

Balance Sheet

The company has 1.18 billion in cash and 2.18 billion in debt, giving a net cash position of -1.00 billion.

Cash & Cash Equivalents	1.18B
Total Debt	2.18B
Net Cash	-1.00B
Net Cash Per Share	n/a
Equity (Book Value)	2.32B
Book Value Per Share	4.20
Working Capital	-113.66M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -62.14 million and capital expenditures -260.54 million, giving a free cash flow of -322.69 million.

Operating Cash Flow	-62.14M
Capital Expenditures	-260.54M
Free Cash Flow	-322.69M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 83.28%, with operating and profit margins of -40.79% and -42.54%.

Gross Margin	83.28%
Operating Margin	-40.79%
Pretax Margin	-42.54%
Profit Margin	-42.54%
EBITDA Margin	-28.57%
EBIT Margin	-40.79%
FCF Margin	n/a

Dividends & Yields

RemeGen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.77%
Shareholder Yield	-0.77%
Earnings Yield	-1.88%
FCF Yield	-0.64%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RemeGen has an Altman Z-Score of 2.83 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.83
Piotroski F-Score	4